📢 We are thrilled to announce the launch of our brand-new website xeltis.com We are dedicated to transforming cardiovascular care and improving outcomes for patients. Today, we take another step forward in achieving that mission with our revamped online presence.

Today @Xeltis announces that it has secured nearly €50m from the @EIB and existing shareholders to advance #aXess to the market. Xeltis welcomed Robert de Groot, VP of the EIB, along with Cecilia Thorfinn to the Xeltis headquarters for the official signing ceremony.

We are pleased to announce the publication of 12-month follow-up data on the performance and safety of aXess, our restorative vascular access conduit, in The Journal of Vascular Access. Access the publication here: journals.sagepub.com/doi/10.…

We are thrilled to share that @Xeltis has been awarded Medtech of the Year at the @lifestarsawards 🏆 We are beyond proud to see our hard work and dedication acknowledged. A big thank you to the whole Xeltis team who made this achievement possible!

Next week @Xeltis' CEO Eliane Schutte will be in London for the #LSXInvestivalShowcase! Eliane will moderate a powerhouse discussion with leading #medtech investors to explore the current fundraising landscape and how medtech companies can best position themselves for success.

On Wednesday, Xeltis hosted an Investigator Meeting ahead of the annual @Dialysis_Access (#CiDA) Symposium. It was a fantastic event that brought together several of our study investigators and study teams participating in the aXess US pivotal trial. #PivotalTrial

This week at the @Dialysis_Access CiDA Symposium, Dr. @robertshahverdyan, will present data from @Xeltis’ EU pivotal trial of #aXess 🎤 Innovative Breakthroughs in Dialysis: A Novel Restorative Conduit for Dialysis Access 📅1 November |🕰️10:48 - 10:54 EST #CiDA2025

The @Xeltis team will be attending the annual @Dialysis_Access CiDA Symposium, in Boston, from October 30 - November 1, 2025. Our team will host an exhibitor booth, and be on hand to answer any questions, and @robshahverdyan will present on the EU pivotal trial data for aXess.

@Xeltis CEO Eliane Schutte will be in San Francisco, California, for the @crfheart's 37th Annual TCT Conference from 25 - 28 October. Get in touch to learn more about Xeltis our second product in clinical development, #Xabg, to transform the bypass surgery landscape.

This week, @Xeltis attended the 53rd @EDTNAERCA international conference in Porto, Portugal. Luca Silvagni, Senior Clinical Specialist, delivered a presentation on the early clinical experience of #aXess and the team hosted a cannulation workshop to simulate aXess cannulation

This week, our CEO Eliane Schutte, CMO Paulo Neves, and VP of Clinical Business Development Luc Verhees, will be attending the EACTS Annual Meeting! The team is looking forward to connecting with the global surgical cardiothoracic community. Get in touch to connect!

Xeltis is proud to announce exceptional clinical data from its EU pivotal trial of aXess, its restorative vascular access conduit, underscoring aXess’ transformative potential in hemodialysis treatment. Read the full press release here: xeltis.com/xeltis-poised-for…

This week @Xeltis is in Istanbul, Turkey, for the @ESVSmembership Annual Meeting Esteemed vascular access KOL and investigator Augusto Ministro will present the complete results from the successful EU pivotal Trial 📅 Tuesday 23 September 🕰️ 16:00 – 16:06 GMT +3 📍 Plenary 2B

Today @Xeltis’ CFO Alexander Goemans will be joining a panel discussion at BioWin Days in Namur, Belgium. 🎤Interactive Panel - funding health innovation: Two startups journeys, two investor perspectives 📅 Tuesday 23 September 🕰️13:40 → 14:30 CET #BioWinDays

We are proud to share that our CEO Eliane Schutte has been shortlisted for both CEO of the Year and Women Led Business Leader of the year, while @Xeltis is a finalist for Medtech Company of the year at the 2025 European @lifestarsawards! #EuropeanLifestars #Awards

Our CEO, Eliane Schutte, and CFO, Alexander Goemans, will be heading to London to attend LSI Europe from the 9th - 12th of September! Eliane will deliver a company presentation and will join a panel discussion alongside other leaders in the medtech industry. @lsintelligence

Last week, Prof Frans Moll attended ASVS 2025 in Singapore. He delivered a presentation titled 'Bioabsorbable conduits for Bypasses' which explored @Xeltis' transformative vascular implants Visit our website to learn more: xeltis.com #ASVS #aXess #VascularAccess

@Xeltis CEO Eliane Schutte spoke with Shani Alexander of BioWorld News on last week's positive data announcement for #Xabg, our coronary artery bypass (CABG) conduit. "It's early, but ... this is going to blow everybody's mind", said Eliane. bit.ly/40xKbG1

On June 5th, @Xeltis brought together a small group of leading European dialysis nurses in vascular access with our clinical development team to share insights on how to enhance healthcare professional training, education, and patient communication for #aXess